Supernus Pharmaceuticals Inc  

(Public, NASDAQ:SUPN)   Watch this stock  
Find more results for SUPN
43.20
+1.35 (3.23%)
After Hours: 43.25 +0.05 (0.12%)
Jun 28, 5:34PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 42.15 - 43.75
52 week 17.25 - 44.95
Open 42.85
Vol / Avg. 0.00/687,677.00
Mkt cap 2.06B
P/E 23.21
Div/yield     -
EPS 1.86
Shares 50.28M
Beta 1.75
Inst. own 96%
Jul 31, 2017
Q2 2017 Supernus Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 13, 2017
Supernus Pharmaceuticals Inc Annual Shareholders Meeting
Jun 7, 2017
Supernus Pharmaceuticals Inc at Jefferies Healthcare Conference
May 19, 2017
Supernus Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
May 10, 2017
Q1 2017 Supernus Pharmaceuticals Inc Earnings Call - Webcast
May 9, 2017
Q1 2017 Supernus Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 17.88% 42.43%
Operating margin 28.98% 24.90%
EBITD margin - 26.33%
Return on average assets 13.07% 36.62%
Return on average equity 20.76% 65.21%
Employees 363 -
CDP Score - -

Address

1550 E Gude Dr
ROCKVILLE, MD 20850-1339
United States - Map
+1-301-8382500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Officers and directors

Charles W. Newhall III Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Jack A. Khattar President, Chief Executive Officer, Secretary, Director
Age: 55
Bio & Compensation  - Reuters
Gregory S. Patrick Chief Financial Officer, Vice President
Age: 65
Bio & Compensation  - Reuters
Stefan K. F. Schwabe M.D. Ph.D. Executive Vice-President - Research and Development, Chief Medical Officer
Age: 65
Bio & Compensation  - Reuters
Padmanabh P. Bhatt Ph.D. Senior Vice President - Intellectual Property, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Victor Vaughn Senior Vice President - Sales and Marketing
Age: 59
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 71
Bio & Compensation  - Reuters
William A. Nuerge Independent Director
Age: 64
Bio & Compensation  - Reuters
John M. Siebert Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters